Home
0086-571-8627 3270
service@chemball.com
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >
Alogliptin Benzoate
CAS NO.: 850649-62-6
FOB Price: NEGOTIABLE Get Latest Price
Specification: ≥99.5%
Documentation: Get COA after inquiry
Lead Time: 14-30 days
Max Capacity: -
Packing: 25KG/Fibre Drum
Product Detail
Properties

Alogliptin Benzoate


Synonymous:

Alogliptin

CAS:

850649-62-6

Molecular Formula:

C18H21N5O2C7H6O2

Molecular Weight:

461.51

Appearance

white powder

Storage

Room temperature storage

Category

Treatment of type II diabetes mellitus


Pharmacological action:

Incretin is a peptide hormone produced by gastrointestinal tract after meal, which can promote islet growth β Cells secrete insulin, It includes glucagon like peptide-1 (GLP-1 and Glucose dependent insulinotropic peptide (GIP) secretion from L cells and duodenal K cells in ileum and colon respectively. GLP-1 and GIP can release into the blood circulation within minutes after taking food, but are rapidly inactivated by serine protease DPP-4. In type 2 diabetes patients, the level of incretin insulin in the body decreases significantly, thus preventing incretin inactivation. Time will effectively reduce blood sugar. As a DPP-4 inhibitor, agliptin benzoate can selectively inhibit DPP-4, reduce the inactivation of GLP-1 in vivo, increase the level of GLP-1 in vivo, and reduce blood glucose. When the blood glucose drops to the normal level, it will not continue to play a hypoglycemic role, so it can effectively reduce the risk of hypoglycemia. In addition, DPP-4 inhibitor can delay gastric emptying, increase satiety, inhibit appetite and help patients reduce body weight. Therefore, these drugs can effectively reduce blood sugar, but also reduce the risk of hypoglycemia and body weight gain, overcome the obstacles of patients reaching the standard, and bring new hope to the treatment of diabetes.


Security:

A Glenn Dean's single drug therapy or combination with other hypoglycemic drugs is usually well tolerated in type 2 diabetic patients with poor glycemic control. The risk of hypoglycemia caused by the drug is low, which is ≤ 8.3% in the agliptin treatment group and ≤ 10.5% in the placebo group, respectively, and there is no significant difference between young and elderly patients. The long-term safety of agliptin remains to be investigated in clinical practice and clinical research.


Adverse reactions:

The most common adverse reactions of agliptin benzoate were nasopharyngitis, headache and upper respiratory tract infection. Most adverse reactions were mild to moderate and had no correlation with dose.

Send your message to this supplier
To:
JIANGSU WISDOM PHARMACEUTICAL CO.,LTD
From:
Please enter your email
Message:
You did not fill in the message!
You can upload 6 files at most
Add Attachment
SEND SUCCESSFUL!
SEND FAILED
Not exactly what you want? One request, multiple quotations Get Quotations Now >>
24YRS
Business Type:
Manufacturing
Country/Region:
Jiangsu, China
Contacts:
Manager Sha
Position Title:
Sales Manager
Tel:
0086-513- 81292228
Visit Factory
Get Free Samples
Less than 1KG required
Please enter the correct email address
Please enter quantity
Please enter remark